New Weight-Loss Pill Beats Oral Wegovy in Major Trial

ବ୍ୟବସାୟ

ସାଗରମାଳା ଯୋଜନାରେ ଓଡ଼ିଶାକୁ ବଡ଼ ପ୍ରୋତ୍ସାହନ: ୫୬ ହଜାର କୋଟିର...

July 22, 2026

ପାରାଦୀପରେ ହେବ ୫୦୦ କୋଟି ଟଙ୍କାର କ୍ରିଟିକାଲ୍ ମିନେରାଲ୍ ପ୍ରୋସେସିଂ...

July 22, 2026

ଆଦାନୀ ଏନର୍ଜିର ବଡ଼ ସଫଳତା: ପ୍ରଥମ ତ୍ରୟମାସିକରେ ୧୨୪% ବଢ଼ିଲା...

July 21, 2026

ଲୋୟର ସୁକତେଲ ପ୍ରକଳ୍ପକୁ ନେଇ ପୁଣି ବଢ଼ିଲା ଉତ୍ତେଜନା, ଗ୍ରାମ...

July 21, 2026

ମନୋରଞ୍ଜନ

ସ୍ୱାମୀ ୱିଲିୟମ୍ ଇସମାଏଲଙ୍କ ସହ ବିବାହର ଅଦେଖା ଫଟୋ ସେୟାର...

July 21, 2026

‘ଅୱାରାପନ୍ ୨’ର ‘ୟେ ଅୱାରାପନ୍’ ଗୀତ ରିଲିଜ୍: ଅରିଜିତ୍ ସିଂହଙ୍କ...

July 21, 2026

MCUରେ ପୁଣି ଫେରୁଛନ୍ତି ଡେଡପୁଲ୍! ରାୟାନ୍ ରେନୋଲ୍ଡସଙ୍କ ବଡ଼ ସଙ୍କେତ,...

July 20, 2026

ଡେଲିଭରି ପରେ ମାତ୍ର କିଛି ମାସରେ ଫିଟ୍ ହୋଇଥିଲେ ଆଲିଆ...

July 20, 2026

New Weight-Loss Pill Beats Oral Wegovy in Major Trial

A new oral weight-loss pill — orforglipron — has outperformed oral semaglutide (Wegovy) in a large head-to-head clinical trial, showing greater average weight loss and better blood sugar control. The results suggest a promising new treatment option as obesity drug developers race for approvals.

Published by Somesh | February 26, 2026

In a major development for obesity and metabolic health treatment,Eli Lilly’s experimental oral GLP-1 therapy, orforglipron, demonstrated superior results compared withoral semaglutide (Wegovy)in a largePhase 3 head-to-head trialinvolving nearly 1,700 participants with type 2 diabetes and overweight conditions. TheACHIEVE-3study, published inThe Lancet, showed that orforglipron — taken once daily — delivered significantly greater improvements inweight loss and blood sugar controlcompared with semaglutide at key measured doses, with results emerging as early as four weeks and sustained throughout the study period.

Participants receiving orforglipron experienced more substantial average weight reduction and larger drops inA1C(a key marker of blood glucose levels) than those on the semaglutide regimen, highlighting its potential dual benefit in metabolic and obesity management. Unlike semaglutide, which is often taken under fasted conditions, orforglipron does not require fasting before dosing, offering easier administration for patients. While exact regulatory timelines are pending, orforglipron’s performance positions it as a strong candidate to expand the oral GLP-1 therapeutic landscape if approved for obesity indications.

Experts note that this milestone underscores intense competition in the weight-loss drug market, where multiple companies are racing to develop effective, convenient, and accessible oral treatments. Patients seeking options beyond injectable therapies — such as weekly GLP-1 injections — may benefit from the emerging crop of oral agents, but the long-term safety profiles and regulatory decisions will be key to widespread adoption.